Bai Y - Search Results

1

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Zhang X, et al. Among authors: bai y. Lancet Oncol. 2021 Aug;22(8):1081-1092. doi: 10.1016/S1470-2045(21)00297-7. Epub 2021 Jul 9. Lancet Oncol. 2021. PMID: 34252374 Clinical Trial.

2

[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].

Hu B, Yu JR, Wen ZZ, Shu YQ, Wang BC, Yin HR, Chen L, Bai YX, Liang J, Chen L, Cheng Y, Shen L, Zhou Y, Zhang HG, Li J, Wan DS, Chen S, Jia TZ, Jin ML. Hu B, et al. Among authors: bai yx. Zhonghua Zhong Liu Za Zhi. 2008 Dec;30(12):940-3. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173999 Clinical Trial. Chinese.

3

[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].

Zhang SH, Jiang ZF, Xie XD, Wei Y, Ren J, Liu JW, Liu WC, Li X, Bai YX, Jiao SC, Sun Q, Liu DQ, Xiao JX, Wang HQ, Tang LL, Cheng Y, Wang Y, Wang YS. Zhang SH, et al. Among authors: bai yx. Zhonghua Yi Xue Za Zhi. 2010 Jul 13;90(26):1813-5. Zhonghua Yi Xue Za Zhi. 2010. PMID: 20979824 Clinical Trial. Chinese.

4

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Ohtsu A, et al. J Clin Oncol. 2013 Nov 1;31(31):3935-43. doi: 10.1200/JCO.2012.48.3552. Epub 2013 Sep 16. J Clin Oncol. 2013. PMID: 24043745 Free PMC article. Clinical Trial.

5

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.

Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y. Deng T, et al. Among authors: bai yx. Med Oncol. 2013 Dec;30(4):752. doi: 10.1007/s12032-013-0752-z. Epub 2013 Oct 31. Med Oncol. 2013. PMID: 24174316 Clinical Trial.

6

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF, Lin LZ, Wang JW, Xiong JP, Wu CP, Li J, Liu YP, Wang D, Ba Y, Feng JP, Bai YX, Bi JW, Ma LW, Lei J, Yang Q, Yu H. Xu RH, et al. Among authors: bai yx. Chin J Cancer. 2017 Dec 22;36(1):97. doi: 10.1186/s40880-017-0263-y. Chin J Cancer. 2017. PMID: 29273089 Free PMC article. Clinical Trial.

7

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells.

Xie R, Liu J, Yu X, Li C, Wang Y, Yang W, Hu J, Liu P, Sui H, Liang P, Huang X, Wang L, Bai Y, Xue Y, Zhu J, Fang T. Xie R, et al. Among authors: bai y. J Oncol. 2019 May 2;2019:4035460. doi: 10.1155/2019/4035460. eCollection 2019. J Oncol. 2019. PMID: 31186633 Free PMC article.

8

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.

9

Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study.

Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH. Wang F, et al. Among authors: bai yx. Am J Cancer Res. 2020 Sep 1;10(9):3037-3046. eCollection 2020. Am J Cancer Res. 2020. PMID: 33042632 Free PMC article.

10

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.

Xu J, Xu N, Bai Y, Liu R, Mao C, Sui H, Wang X, Jiang Q, Dou Y. Xu J, et al. Among authors: bai y. Oncoimmunology. 2020 Dec 31;10(1):1864908. doi: 10.1080/2162402X.2020.1864908. Oncoimmunology. 2020. PMID: 33457083 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,622 results

Search Page